Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma

Lignende værker

• The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy
  af: Furubayashi, Nobuki, et al.
  Udgivet: (2017)
• Biochemical failure after radical prostatectomy in intermediate-risk group men increases with the number of risk factors
  af: Furubayashi, Nobuki, et al.
  Udgivet: (2017)
• Positive resection margins may not reflect the true margin in patients undergoing radical prostatectomy
  af: FURUBAYASHI, NOBUKI, et al.
  Udgivet: (2014)
• Patients treated with radical prostatectomy with positive digital rectal examination findings in the intermediate-risk group are prone to PSA recurrence
  af: FURUBAYASHI, NOBUKI, et al.
  Udgivet: (2016)
• Determination of adequate pelvic lymph node dissection range for Japanese males undergoing radical prostatectomy
  af: Furubayashi, Nobuki, et al.
  Udgivet: (2017)